Nano Dimension Announces 2022 Revenue of $43.6M
March 30, 2023 08:27 ET
|
Nano Dimension Ltd.
316% Growth for Full Year 2022 Over 20212022 Revenue is 1,200% Higher than 2020Q4/2022 Revenue of $12.1M is 61% Higher Than Q4/2021and 21% Higher Than Q3/2022 Waltham, Mass, March 30, 2023 ...
Clearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
May 26, 2022 09:30 ET
|
Clearmind Medicine Inc.
Clearmind aims to initiate clinical trials with CMND-100 by year’s end VANCOUVER, May 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the...
Enlivex Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients
May 25, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Grant provides $1.2 million in non-dilutive funding for 2022 sepsis clinical trial expensesTo date, Enlivex has received a total of $7.8 million in non-dilutive grants from the Israel Innovation...
Clearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET
|
Clearmind Medicine Inc.
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 ...
SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment
May 24, 2022 08:30 ET
|
SciSparc Ltd
Pre-clinical trials based on the proprietary combination demonstrate significant suppressive effect on alcohol consumption TEL AVIV, Israel, May 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
August 15, 2018 08:50 ET
|
GB Sciences, Inc.
Las Vegas, NV, Aug. 15, 2018 (GLOBE NEWSWIRE) -- For the three months that ended June 30, 2018, GB Sciences, Inc. (OTCQB: GBLX) reported revenue of $1,315,284 and gross profit of $734,719. This...
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
July 31, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, July 31, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc (OTCQB:GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance...